FindTrial
Sign In

CARBOPLATINE KABI 10 mg/ml

DRUG2 trials

Sponsors

Institut Gustave Roussy

Conditions

Non-seminomatous germ-cell tumors (including testisSynchronous oligometastatic non-small cell lung cancer (NSCLC)retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified as poor prognosis according to IGCCCG criteria.

Phase 2

A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06))
RecruitingCTIS2023-505040-19-00
Institut Gustave RoussyNon-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified as poor prognosis according to IGCCCG criteria.
Start: 2023-04-11Target: 150Updated: 2025-03-14

Phase 3

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)
RecruitingCTIS2023-503326-39-00
Institut Gustave RoussySynchronous oligometastatic non-small cell lung cancer (NSCLC)
Start: 2025-03-06Target: 130Updated: 2025-08-26